Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 3.31 million shares were traded. OPK stock price reached its highest trading level at $1.35 during the session, while it also had its lowest trading level at $1.22.
Ratios:
For a deeper understanding of Opko Health Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.32 and its Current Ratio is at 3.70. In the meantime, Its Debt-to-Equity ratio is 0.30 whereas as Long-Term Debt/Eq ratio is at 0.28.
Barrington Research Upgraded its Mkt Perform to Outperform on June 29, 2023, while the target price for the stock was maintained at $2.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 31 ’25 when FROST PHILLIP MD ET AL bought 150,000 shares for $1.42 per share. The transaction valued at 213,435 led to the insider holds 214,386,448 shares of the business.
FROST PHILLIP MD ET AL bought 675,000 shares of OPK for $891,000 on Aug 08 ’25. The CEO & Chairman now owns 214,676,448 shares after completing the transaction at $1.32 per share. On Apr 10 ’25, another insider, FROST PHILLIP MD ET AL, who serves as the CEO & Chairman of the company, bought 125,000 shares for $1.36 each. As a result, the insider paid 169,712 and bolstered with 214,001,448 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OPK now has a Market Capitalization of 1021042688 and an Enterprise Value of 1004490688. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.59 while its Price-to-Book (P/B) ratio in mrq is 0.78. Its current Enterprise Value per Revenue stands at 1.564 whereas that against EBITDA is -8.673.
Stock Price History:
The Beta on a monthly basis for OPK is 1.34, which has changed by -0.16874999 over the last 52 weeks, in comparison to a change of 0.14151978 over the same period for the S&P500. Over the past 52 weeks, OPK has reached a high of $2.04, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -8.54%, while the 200-Day Moving Average is calculated to be -8.89%.
Shares Statistics:
For the past three months, OPK has traded an average of 2.19M shares per day and 2716980 over the past ten days. A total of 768.70M shares are outstanding, with a floating share count of 394.08M. Insiders hold about 48.67% of the company’s shares, while institutions hold 28.64% stake in the company. Shares short for OPK as of 1761868800 were 32755482 with a Short Ratio of 15.24, compared to 1759190400 on 33683158. Therefore, it implies a Short% of Shares Outstanding of 32755482 and a Short% of Float of 7.4499995.
Earnings Estimates
. The current market rating for Opko Health Inc (OPK) reflects the collective analysis of 1 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.08 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.3 and -$0.35 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is -$0.31, with 1 analysts recommending between -$0.31 and -$0.31.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $140.22M this quarter.It ranges from a high estimate of $147.4M to a low estimate of $137.5M. As of. The current estimate, Opko Health Inc’s year-ago sales were $183.6MFor the next quarter, 6 analysts are estimating revenue of $130.8M. There is a high estimate of $134.8M for the next quarter, whereas the lowest estimate is $127.9M.
A total of 6 analysts have provided revenue estimates for OPK’s current fiscal year. The highest revenue estimate was $605.8M, while the lowest revenue estimate was $595.9M, resulting in an average revenue estimate of $598.63M. In the same quarter a year ago, actual revenue was $713.1MBased on 6 analysts’ estimates, the company’s revenue will be $569.8M in the next fiscal year. The high estimate is $646.4M and the low estimate is $535M.
